Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
VCRE Account Payables
Amounts the company owes suppliers for goods and services received.
Vicore Pharma Holding ABNASDAQ: VCRE
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables of SEK 2.06M in Q2 FY2026
Q2 FY2026 account payables was SEK 2.06M.
Context
- Account payables amounted to 2.2% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
SEK · from the balance sheet
- Latest · FY2025
- 39.47M SEK
- Year-over-year change
- —
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.47M | — |
Account Payables vs competitors
How VCRE compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Account payables amounts to 2.2% of total assets for VCRE, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $12.75M USD | +12.4% | +18.7% | 2.4% | |
VCREVicore Pharma Holding AB | Jun 2026 | SEK 2.06M SEK | — | — | 2.2% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding VCRE) | — | +12.4% | +18.7% | 2.4% | |
Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Vicore Pharma Holding AB
NASDAQ:VCRE
Intrinsic Alpha fair value
Locked
Current Price
$9.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.